Dosing & Uses
Dosage Forms & Strengths
tablet, immediate release
- 1mg
- 2mg
capsule, extended release
- 2mg
- 4mg
Overactive Bladder, Urge Incontinence
Immediate release: 2 mg PO q12hr; may lower dose to 1 mg twice daily based on response and tolerability
Extended release: 2-4 mg PO once daily; may lower dose to 1 mg twice daily based on response and tolerability
Dosing Modifications
Renal impairment
- CrCl 10-30 mL/min: Not to exceed 1 mg PO q12hr (immediate release) or 2 mg PO once daily (extended release)
- CrCl <10 mL/min: Not recommended
Hepatic impairment
- Mild to moderate (Child-Pugh class A or B): Not to exceed 1 mg PO q12hr (immediate release) or 2 mg PO once daily (extended release)
- Severe (Child-Pugh class C): Not recommended
Strong CYP3A4 inhibitors
- Not to exceed 1 mg PO q12hr (immediate release) or 2 mg PO once daily (extended release)
Not recommended
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
>10%
Dry mouth (40%)
1-10%
Blurred vision
Constipation
Dizziness
Drowsiness
Dyspepsia
Headache
Xerophthalmia
Warnings
Contraindications
Urinary or gastric retention
Uncontrolled narrow-angle glaucoma
Hypersensitivity to drug or ingredients or to fesoterodine fumarate, which is metabolized to 5-hydroxymethyl tolterodine
Cautions
Controlled narrow-angle glaucoma, hepatic, or renal impairment
Anaphylaxis and angioedema necessitating hospitalization and emergency treatment reported with first or subsequent doses; discontinue immediately if angioedema and hypotension, difficulty breathing, or airway obstruction develop
Anticholinergic central nervous system effects (eg, dizziness, somnolence) reported; patients should not drive or operate heavy machinery until they adjust to therapy
Use with caution in patients with myasthenia gravis, which is characterized by decreased cholinergic activity at neuromuscular junction
When coadministered with strong CYP3A4 inhibitors, tolterodine should be given at reduced dosage
QTc prolongation reported with high doses; use caution in patients with congenital prolonged QT or in patients receiving concurrent therapy with QTc-prolonging drugs (class Ia or III antiarrhythmics)
Anticholinergics may potentially adversely affect the clinical course of alzheimer disease in patients receiving cholinesterase inhibitors; monitor for decreases in congnition, functional abilities and increased problematic behaviors in patients with dementia receiving dual therapy with an anticholinesterase inhibitor and a bladder anticholinercgic agent like tolterodine
May increase risk of urinary retention in patients with bladder flow obstruction (eg, benign prostatic hypertrophy)
May increase risk of gastric retention in patients with decreased GI motility or gastrointestinal obstructive disorders
Pregnancy & Lactation
Pregnancy
There are no available data with use in pregnant women to inform drug-associated risks; in animal reproduction studies, oral administration of tolterodine and its 5-HMT metabolite to pregnant mice during organogenesis did not produce adverse developmental outcomes at doses approximately 9 to 12 times the clinical exposure at a dose of 20 mg/kg/day; however, higher doses produced adverse developmental outcomes
Lactation
There is no information on presence in human milk, effects on breastfed infant, or on milk production; based on limited data, tolterodine is excreted into milk in mice in low amounts; the development and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from drug or from underlying maternal condition
Pregnancy Categories
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Pharmacology
Mechanism of Action
Competitive muscarinic receptor antagonist; decreases bladder contractions; is more specific for bladder than oxybutynin
Absorption
Bioavailability: 77%
Onset: Overactive bladder, 1 wk; urge incontinence, 1 hr
Time to peak effect: 2-4 wk
Peak plasma time: Immediate release, 1-2 hr; extended release, 2-6 hr
Distribution
Vd: 113 L
Metabolism
Metabolized in liver by CYP2D6 and (to minor extent) CYP3A4
Metabolites: 5-Hydroxymethyl, dealkylated tolterodine
Elimination
Half-life: Parent drug, 1.9-3.7 hr; active metabolite (5-hydroxymethyl), 3 hr (8.7 hr in cirrhosis)
Total body clearance: 5.7 L/kg/hr
Excretion: Urine (77%), feces (17%)
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
